Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 7/20 | 0.56 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 4/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5955202 | 0.84 | FAAH (0.48) | DAGLAFAAHCES1XDHELANE | |
| SCHEMBL7394467 | 0.84 | FAAH (0.48) | DAGLAFAAHCES1XDHELANE | |
| SCHEMBL6466904 | 0.81 | DAGLA (0.50) | DAGLAFAAHCES1XDHELANE | |
| SCHEMBL5420243 | 0.81 | ELANE (0.48) | DAGLAFAAHCES1XDHELANE | |
| SCHEMBL14973780 | 0.81 | ELANE (0.48) | DAGLAFAAHCES1XDHELANE | |
| Hydrochloric Acid SCHEMBL5421089 | 0.80 | ELANE (0.47) | DAGLAFAAHCES1XDHELANE | |
| SCHEMBL14378300 | 0.79 | DAGLA (0.54) | DAGLAFAAHCES1XDHKDM4E | |
| SCHEMBL6466589 | 0.78 | DAGLA (0.56) | DAGLAFAAHCES1XDHNPC1 | |
| SCHEMBL6466909 | 0.78 | DAGLA (0.56) | DAGLAFAAHCES1XDHNPC1 | |
| SCHEMBL6465885 | 0.78 | XDH (0.47) | DAGLAFAAHCES1XDHELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1399146-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARM INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | AXYS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| EP-1399146-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098406-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | DAGLA 1772/4885FAAH 602/4885CES1 154/4885 |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | CAPNS1, CTSS, CTSV | DAGLA 3145/4885FAAH 3742/4885CES1 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.